Close Menu

NEW YORK (GenomeWeb) – RTI and Asuragen today announced a collaboration to perform high-throughput screening testing for fragile X syndrome in newborns.

Using Asuragen's technology, screening will be conducted in North Carolina's Early Check study, a free screening study to identify children with rare health conditions before symptoms appear and assess the value of benefits of early intervention. With a mother's consent, Early Check reuses the same blood sample taken for regular newborn screening to test for additional conditions, such as fragile X syndrome.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.